Sökning: onr:"swepub:oai:DiVA.org:umu-224940" >
Beta-blocker bashin...
Beta-blocker bashing and downgrading in hypertension management : A fashionable trend representing a matter of concern
-
- Kreutz, Reinhold (författare)
- Charite-Universitätsmedizin Berlin, Institute of Clinical Pharmacology and Toxicology, Germany
-
- Brunström, Mattias (författare)
- Umeå universitet,Institutionen för folkhälsa och klinisk medicin
-
- Burnier, Michel (författare)
- Faculty of Biology and Medicine, University of Lausanne, Switzerland
-
visa fler...
-
- Grassi, Guido (författare)
- Clinica Medica, University Milano-Bicocca, Milan, Italy
-
- Januszewicz, Andrzej (författare)
- Department of Hypertension, National Institute of Cardiology, Warsaw, Poland
-
- Kjeldsen, Sverre E. (författare)
- Institute for Clinical Medicine, University of Oslo, Norway
-
- Muiesan, Maria L. (författare)
- Departments of Cardiology and Nephrology, Ullevaal Hospital, Oslo, Norway; OC 2 Medicina, ASST Spedali Civili di Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Italy
-
- Thomopoulos, Costas (författare)
- Department of Cardiology, General Hospital of Athens Laiko, Greece
-
- Tsioufis, Konstantinos (författare)
- First Department of Cardiology, Medical School, University of Athens, Hippokration Hospital, Athens, Greece
-
- Mancia, Giuseppe (författare)
- University Milano-Bicocca, Italy
-
visa färre...
-
(creator_code:org_t)
- Wolters Kluwer, 2024
- 2024
- Engelska.
-
Ingår i: Journal of Hypertension. - : Wolters Kluwer. - 0263-6352 .- 1473-5598. ; 42:6, s. 966-967
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- In their commentary, Shantsila et al.[1] while discussing some relevant issues of the 2023 Guidelines for the Management of Hypertension of the European Society of Hypertension (ESH) [2], for example, the length of the text and the involvement of only a few primary care physicians, they largely focus on the discussion on beta-blockers. The authors conclude that ‘the 2023 ESH Guidelines still argue in favour of beta-blockers that their clinical inferiority was simply to lesser blood pressure (BP) reduction rather than class effect’. However, this is an oversimplification that does not reflect the numerous arguments and facts that support the overall rationale of the 2023 ESH Guidelines for the recommended use of beta-blockers in the management of hypertension [2]. Taken together with other similar comments [3], it appears that it has become fashionable to down-grade beta-blockers and to dismiss the points already put forward in the 2023 ESH guidelines [2] and in previous publications revisiting beta-blocker benefits in detail [4,5]. Against this background, we use this opportunity to emphasize on key aspects of the beta-blocker discussion in brief. For a more comprehensive review of the literature, we refer to a very recent publication by us regarding the role of beta-blocker in hypertension [6].
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Kreutz, Reinhold
-
Brunström, Matti ...
-
Burnier, Michel
-
Grassi, Guido
-
Januszewicz, And ...
-
Kjeldsen, Sverre ...
-
visa fler...
-
Muiesan, Maria L ...
-
Thomopoulos, Cos ...
-
Tsioufis, Konsta ...
-
Mancia, Giuseppe
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
Journal of Hyper ...
- Av lärosätet
-
Umeå universitet